Genetic Technologies (ASX:GTG)

Genetic Technologies (ASX:GTG) Limited offers predictive testing and assessment tools to help physicians proactively manage women’s health. The Company’s lead product,BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class.

Latest Article

GTG Validates Cancer Tests As it Looks to Global Expansion

GTG Validates Cancer Tests As it Looks to Global Expansion

What if there was a cost effective way for patients to assess their cancer risk and seek treatment? There is. Genetic Technologies (ASX:GTG; NASDAQ:GENE).

READ ARTICLE

Related Genetic Technologies (ASX:GTG) articles

ASX Med-Tech’s Genetic Cancer Screening Enters China, Eyes Future Asian Growth

ASX Med-Tech’s Genetic Cancer Screening Enters China, Eyes Future Asian Growth

Genetic Technologies (ASX:GTG) is a provider of world-leading genetic risk assessment test products.

READ ARTICLE

Top Trending

Thanks for subscribing!

X